Knowles Julius sold $28K of KROS
Knowles Julius sold 2,625 shares of Keros Therapeutics, Inc. (KROS) at $10.73 on 2026-06-04 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosure provides a concrete ownership-change datapoint but does not introduce new company fundamentals in the text.
Market read
A director’s 10b5-1 sale is disclosed; absent other catalysts, it is typically a low-signal event for trading.
What to watch
The filing does not reveal intent beyond the plan; traders should check for clustering of insider sales, changes in other directors/officers, and any concurrent company disclosures.
Background
The article is an SEC Form 4 insider transaction filing (director sale) for Keros Therapeutics.
Ticker impact
Director Knowles Julius sold 2,625 Keros Therapeutics shares in an open-market transaction under a pre-arranged 10b5-1 plan.
Low near-term impact; any reaction is likely muted unless accompanied by other negative company-specific news.
This is a Form 4 insider sale with a stated 10b5-1 plan and no accompanying operational/regulatory/financial catalyst in the text.
Market effects
No sector read-through; single-company insider transaction without new clinical/financial/regulatory facts.
None indicated.
None indicated.
Counterpoint
Even 10b5-1 sales can coincide with internal risk reassessments; if volume/insider selling accelerates, it could become a bearish technical/positioning signal.
Key entities
- issuerKeros Therapeutics, Inc.
Subject of the Form 4 insider transaction disclosure.
- insiderKnowles Julius
Director who executed an open-market sale under a pre-arranged 10b5-1 plan.